CoChat
Sign Up
Cited by 70

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction

Segovia-Zafra, Antonio, Di Zeo-Sánchez, Daniel E., López-Gómez, Carlos, Pérez-Valdés, Zeus, García-Fuentes, Eduardo, Andrade, Raúl J., Lucena, M. Isabel, Villanueva-Paz, Marina·2021·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2021.11.013PMC PMC8727925
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2021.11.013

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Strategies employed by the pharmaceutical industry to screen for hepatotoxic substances during drug development have not prevented drugs with hepatotoxic potential from entering clinical development.

    “These strategies, which include toxicological studies in experimental animals and in silico models for simultaneously screening a multitude of hepatotoxic molecules, have not prevented drugs with hepatotoxic potential from entering clinical development [17].”

    From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [17]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 386

  1. Chen, 2015, Drug-induced liver injury: interactions between drug properties and host factors, J Hepatol, 63, 503, 10.1016/j.jhep.2015.04.016 · DOI
  2. Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI
  3. de Abajo, 2004, Acute and clinically relevant drug-induced liver injury: a population based case-control study, Br J Clin Pharmacol, 58, 71, 10.1111/j.1365-2125.2004.02133.x · DOI
  4. De Valle, 2006, Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic, Aliment Pharmacol Ther, 24, 1187, 10.1111/j.1365-2036.2006.03117.x · DOI
  5. Kullak-Ublick, 2017, Drug-induced liver injury: recent advances in diagnosis and risk assessment, Gut, 66, 1154, 10.1136/gutjnl-2016-313369 · DOI · Paper page
  6. Kuna, 2018, Models of drug induced liver injury (DILI)—current issues and future perspectives, Curr Drug Metab, 19, 830, 10.2174/1389200219666180523095355 · DOI · Paper page
  7. Robles-Diaz, 2014, Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury, Gastroenterology, 147, 109, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  8. Ashby, 2021, Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI, J Hepatol, 75, 333, 10.1016/j.jhep.2021.03.021 · DOI
  9. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin Pharmacol Ther, 89, 806, 10.1038/clpt.2011.58 · DOI
  10. Lucena, 2020, Drug-induced liver injury in older people, Lancet Gastroenterol Hepatol, 5, 862, 10.1016/S2468-1253(20)30006-6 · DOI · Paper page
  11. Danan, 1993, Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  12. Ulrich, 2007, Idiosyncratic toxicity: a convergence of risk factors, Annu Rev Med, 58, 17, 10.1146/annurev.med.58.072905.160823 · DOI
  13. Gonzalez-Jimenez, 2019, The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury, Liver Int, 39, 401, 10.1111/liv.13952 · DOI
  14. Macías-Rodríguez, 2020, Reclassifying hepatic cell death during liver damage: ferroptosis-a novel form of non-apoptotic cell death?., Int J Mol Sci, 21, 1651, 10.3390/ijms21051651 · DOI
  15. O'Brien, 2004, Human and animal hepatocytes in vitro with extrapolation in vivo, Chem Biol Interact, 150, 97, 10.1016/j.cbi.2004.09.003 · DOI
  16. Vorrink, 2018, Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions, Toxicol Sci, 163, 655, 10.1093/toxsci/kfy058 · DOI · Paper page
  17. Kamalian, 2015, The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death, Toxicol Vitro, 29, 732, 10.1016/j.tiv.2015.02.011 · DOI · Paper page
  18. Xuan, 2016, Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity, Chem Biol Interact, 255, 63, 10.1016/j.cbi.2015.10.009 · DOI · Paper page
  19. Wink, 2018, Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury, Arch Toxicol, 92, 1797, 10.1007/s00204-018-2178-z · DOI
  20. Antherieu, 2012, Optimization of the HepaRG cell model for drug metabolism and toxicity studies, Toxicol Vitro, 26, 1278, 10.1016/j.tiv.2012.05.008 · DOI
  21. Tolosa, 2016, Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis, Toxicol Appl Pharmacol, 302, 1, 10.1016/j.taap.2016.04.007 · DOI
  22. Choi, 2009, Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells, Xenobiotica, 39, 205, 10.1080/00498250802613620 · DOI
  23. Chu, 2011, Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism, Biotechnol Bioeng, 108, 2932, 10.1002/bit.23256 · DOI
  24. Apostolova, 2011, Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy, Hepatology, 54, 1009, 10.1002/hep.24459 · DOI
  25. Apostolova, 2013, ER stress in human hepatic cells treated with Efavirenz: mitochondria again, J Hepatol, 59, 780, 10.1016/j.jhep.2013.06.005 · DOI
  26. Polo, 2015, Mitochondrial (dys)function—a factor underlying the variability of efavirenz-induced hepatotoxicity?., Br J Pharmacol, 172, 1713, 10.1111/bph.13018 · DOI
  27. Thompson, 2012, In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs, Chem Res Toxicol, 25, 1616, 10.1021/tx300091x · DOI
  28. Yildirimman, 2011, Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity, Toxicol Sci, 124, 278, 10.1093/toxsci/kfr225 · DOI
  29. Kim, 2017, Prediction of drug-induced immune-mediated hepatotoxicity using hepatocyte-like cells derived from human embryonic stem cells, Toxicology, 387, 1, 10.1016/j.tox.2017.06.005 · DOI
  30. Cipriano, 2020, Nevirapine biotransformation insights: an integrated in vitro approach unveils the biocompetence and glutathiolomic profile of a human hepatocyte-like cell 3D model, Int J Mol Sci, 21, 3998, 10.3390/ijms21113998 · DOI
  31. Choudhury, 2017, Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity, Sci Rep, 7, 41238, 10.1038/srep41238 · DOI
  32. Imagawa, 2017, Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells, Sci Rep, 7, 41806, 10.1038/srep41806 · DOI
  33. Deguchi, 2019, Modeling of hepatic drug metabolism and responses in CYP2C19 poor metabolizer using genetically manipulated human iPS cells, Drug Metab Dispos, 47, 632, 10.1124/dmd.119.086322 · DOI
  34. Novik, 2010, A microfluidic hepatic coculture platform for cell-based drug metabolism studies, Biochem Pharmacol, 79, 1036, 10.1016/j.bcp.2009.11.010 · DOI
  35. Nguyen, 2015, Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters, Drug Metab Dispos, 43, 774, 10.1124/dmd.114.061317 · DOI
  36. Baze, 2018, Three-dimensional spheroid primary human hepatocytes in monoculture and coculture with nonparenchymal cells, Tissue Eng Part C Methods, 24, 534, 10.1089/ten.tec.2018.0134 · DOI
  37. Khetani, 2008, Microscale culture of human liver cells for drug development, Nat Biotechnol, 26, 120, 10.1038/nbt1361 · DOI · Paper page
  38. March, 2015, Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens, Nat Protoc, 10, 2027, 10.1038/nprot.2015.128 · DOI
  39. Chan, 2019, Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac, Drug Metab Dispos, 47, 58, 10.1124/dmd.113.053397fullarticlecorrection · DOI
  40. Elferink, 2011, Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes, Toxicol Appl Pharmacol, 253, 57, 10.1016/j.taap.2011.03.010 · DOI
  41. Hadi, 2013, Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury, Chem Res Toxicol, 26, 710, 10.1021/tx300519p · DOI
  42. Ma, 2020, Current advances on 3D-bioprinted liver tissue models, Adv Healthc Mater, 9, e2001517, 10.1002/adhm.202001517 · DOI
  43. Serras, 2021, A critical perspective on 3D liver models for drug metabolism and toxicology studies, Front Cell Dev Biol, 9, 626805, 10.3389/fcell.2021.626805 · DOI · Paper page
  44. Baudoin, 2013, Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips, Xenobiotica, 43, 140, 10.3109/00498254.2012.706725 · DOI
  45. Choucha Snouber, 2013, Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips, Toxicol Sci, 132, 8, 10.1093/toxsci/kfs230 · DOI
  46. Rubiano, 2021, Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation, Clin Transl Sci, 14, 1049, 10.1111/cts.12969 · DOI
  47. Bricks, 2014, Development of a new microfluidic platform integrating co-cultures of intestinal and liver cell lines, Toxicol Vitro, 28, 885, 10.1016/j.tiv.2014.02.005 · DOI
  48. Lin, 2015, The application of engineered liver tissues for novel drug discovery, Expert Opin Drug Discov, 10, 519, 10.1517/17460441.2015.1032241 · DOI
  49. Sison-Young, 2015, Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication, Toxicol Sci, 147, 412, 10.1093/toxsci/kfv136 · DOI
  50. Sison-Young, 2017, A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity, Arch Toxicol, 91, 1385, 10.1007/s00204-016-1745-4 · DOI
  51. den Braver-Sewradj, 2016, Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer, Toxicol Vitro, 33, 71, 10.1016/j.tiv.2016.02.013 · DOI
  52. Inoue, 1989, Nicotinamide prolongs survival of primary cultured hepatocytes without involving loss of hepatocyte-specific functions, J Biol Chem, 264, 4747, 10.1016/S0021-9258(18)83650-X · DOI
  53. Kost, 1991, Effect of 2% dimethyl sulfoxide on the mitogenic properties of epidermal growth factor and hepatocyte growth factor in primary hepatocyte culture, J Cell Physiol, 147, 274, 10.1002/jcp.1041470212 · DOI
  54. Tolosa, 2016, Human upcyte hepatocytes: characterization of the hepatic phenotype and evaluation for acute and long-term hepatotoxicity routine testing, Toxicol Sci, 152, 214, 10.1093/toxsci/kfw078 · DOI
  55. Tolosa, 2019, Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes, Arch Toxicol, 93, 519, 10.1007/s00204-018-2349-y · DOI
  56. Schulz, 2019, NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies, Clin Hemorheol Microcirc, 73, 249, 10.3233/CH-199226 · DOI
  57. Schaefer, 2018, Quantitative expression of hepatobiliary transporters and functional uptake of substrates in hepatic two-dimensional sandwich cultures: a comparative evaluation of upcyte and primary human hepatocytes, Drug Metab Dispos, 46, 166, 10.1124/dmd.117.078238 · DOI
  58. Guo, 2011, Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes, Drug Metab Dispos, 39, 528, 10.1124/dmd.110.035873 · DOI · Paper page
  59. Gerets, 2012, Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins, Cell Biol Toxicol, 28, 69, 10.1007/s10565-011-9208-4 · DOI · Paper page
  60. Aden, 1979, Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line, Nature, 282, 615, 10.1038/282615a0 · DOI
  61. Costantini, 2013, Gene expression signature of human HepG2 cell line, Gene, 518, 335, 10.1016/j.gene.2012.12.106 · DOI
  62. Doostdar, 1988, The influence of culture medium composition on drug metabolising enzyme activities of the human liver derived Hep G2 cell line, FEBS Lett, 241, 15, 10.1016/0014-5793(88)81021-4 · DOI
  63. Tyakht, 2014, RNA-Seq gene expression profiling of HepG2 cells: the influence of experimental factors and comparison with liver tissue, BMC Genom, 15, 1108, 10.1186/1471-2164-15-1108 · DOI
  64. Tolosa, 2018, Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury, Arch Toxicol, 92, 383, 10.1007/s00204-017-2036-4 · DOI
  65. Tolosa, 2013, HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved, Arch Toxicol, 87, 1115, 10.1007/s00204-013-1012-x · DOI
  66. Donato, 2013, Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering, Curr Drug Metab, 14, 946, 10.2174/1389200211314090002 · DOI
  67. Nakabayashi, 1982, Growth of human hepatoma cells lines with differentiated functions in chemically defined medium, Cancer Res, 42, 3858
  68. Louisa, 2016, Differential expression of several drug transporter genes in HepG2 and Huh-7 cell lines, Adv Biomed Res, 5, 104, 10.4103/2277-9175.183664 · DOI
  69. Sivertsson, 2013, Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation, Mol Pharmacol, 83, 659, 10.1124/mol.112.082305 · DOI
  70. Khamphaya, 2018, Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor, Hepatology, 67, 560, 10.1002/hep.29588 · DOI
  71. Mace, 1997, Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines, Carcinogenesis, 18, 1291, 10.1093/carcin/18.7.1291 · DOI
  72. Glaise, 1998, Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines, Cell Growth Differ, 9, 165
  73. Mills, 2004, Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line, J Pharmacol Exp Ther, 309, 303, 10.1124/jpet.103.061713 · DOI
  74. Scott, 2013, Human induced pluripotent stem cells and their use in drug discovery for toxicity testing, Toxicol Lett, 219, 49, 10.1016/j.toxlet.2013.02.020 · DOI
  75. Rambhatla, 2003, Generation of hepatocyte-like cells from human embryonic stem cells, Cell Transplant, 12, 1, 10.3727/000000003783985179 · DOI · Paper page
  76. Lavon, 2004, Differentiation and isolation of hepatic-like cells from human embryonic stem cells, Differentiation, 72, 230, 10.1111/j.1432-0436.2004.07205002.x · DOI
  77. Schwartz, 2005, Defined conditions for development of functional hepatic cells from human embryonic stem cells, Stem Cells Dev, 14, 643, 10.1089/scd.2005.14.643 · DOI
  78. Takayama, 2012, Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4alpha transduction, Mol Ther, 20, 127, 10.1038/mt.2011.234 · DOI
  79. Li, 2019, Generation of qualified clinical-grade functional hepatocytes from human embryonic stem cells in chemically defined conditions, Cell Death Dis, 10, 763, 10.1038/s41419-019-1967-5 · DOI
  80. Xia, 2017, Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions, J Hepatol, 66, 494, 10.1016/j.jhep.2016.10.009 · DOI
  81. Lee, 2012, Comparison of in vitro hepatogenic differentiation potential between various placenta-derived stem cells and other adult stem cells as an alternative source of functional hepatocytes, Differentiation, 84, 223, 10.1016/j.diff.2012.05.007 · DOI
  82. Cipriano, 2017, The role of epigenetic modifiers in extended cultures of functional hepatocyte-like cells derived from human neonatal mesenchymal stem cells, Arch Toxicol, 91, 2469, 10.1007/s00204-016-1901-x · DOI
  83. Moon, 2011, Reprogramming fibroblasts into induced pluripotent stem cells with Bmi1, Cell Res, 21, 1305, 10.1038/cr.2011.107 · DOI
  84. Si-Tayeb, 2010, Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells, Hepatology, 51, 297, 10.1002/hep.23354 · DOI · Paper page
  85. Takata, 2011, Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines, Hepatol Int, 5, 890, 10.1007/s12072-011-9251-5 · DOI
  86. Nakamura, 2012, Feeder-free and serum-free production of hepatocytes, cholangiocytes, and their proliferating progenitors from human pluripotent stem cells: application to liver-specific functional and cytotoxic assays, Cell Reprogr, 14, 171, 10.1089/cell.2011.0064 · DOI
  87. Schwartz, 2014, Pluripotent stem cell-derived hepatocyte-like cells, Biotechnol Adv, 32, 504, 10.1016/j.biotechadv.2014.01.003 · DOI
  88. Li, 2015, Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model, Hepatology, 61, 1730, 10.1002/hep.27712 · DOI
  89. Pfeiffer, 2015, Featured Article: isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells, Exp Biol Med (Maywood), 240, 645, 10.1177/1535370214558025 · DOI
  90. Granitzny, 2017, Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: a pilot study, Toxicol Rep, 4, 89, 10.1016/j.toxrep.2017.02.001 · DOI
  91. Gripon, 2002, Infection of a human hepatoma cell line by hepatitis B virus, Proc Natl Acad Sci U S A, 99, 15655, 10.1073/pnas.232137699 · DOI
  92. Le Vee, 2013, Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells, Toxicol Vitro, 27, 1979, 10.1016/j.tiv.2013.07.003 · DOI
  93. Josse, 2008, Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies, Drug Metab Dispos, 36, 1111, 10.1124/dmd.107.019901 · DOI
  94. Antherieu, 2011, Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells, Hepatology, 53, 1895, 10.1002/hep.24290 · DOI
  95. Jenne, 2013, Immune surveillance by the liver, Nat Immunol, 14, 996, 10.1038/ni.2691 · DOI · Paper page
  96. Olsen, 2011, Hepatic stellate cells require a stiff environment for myofibroblastic differentiation, Am J Physiol Gastrointest Liver Physiol, 301, G110, 10.1152/ajpgi.00412.2010 · DOI · Paper page
  97. Ware, 2018, A cell culture platform to maintain long-term phenotype of primary human hepatocytes and endothelial cells, Cell Mol Gastroenterol Hepatol, 5, 187, 10.1016/j.jcmgh.2017.11.007 · DOI
  98. Khetani, 2013, Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans, Toxicol Sci, 132, 107, 10.1093/toxsci/kfs326 · DOI
  99. Lin, 2016, Prediction of drug clearance and drug–drug interactions in microscale cultures of human hepatocytes, Drug Metab Dispos, 44, 127, 10.1124/dmd.115.066027 · DOI
  100. Graaf, 2007, Precision-cut tissue slices as a tool to predict metabolism of novel drugs, Expert Opin Drug Metab Toxicol, 3, 879, 10.1517/17425255.3.6.879 · DOI
  101. Vickers, 2006, Consequences of mitochondrial injury induced by pharmaceutical fatty acid oxidation inhibitors is characterized in human and rat liver slices, Toxicol Vitro, 20, 1173, 10.1016/j.tiv.2006.01.021 · DOI · Paper page
  102. Edwards, 2003, Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices, Drug Metab Dispos, 31, 282, 10.1124/dmd.31.3.282 · DOI
  103. Starokozhko, 2017, Maintenance of drug metabolism and transport functions in human precision-cut liver slices during prolonged incubation for 5 days, Arch Toxicol, 91, 2079, 10.1007/s00204-016-1865-x · DOI
  104. Palma, 2019, Precision-cut liver slices: a versatile tool to advance liver research, Hepatol Int, 13, 51, 10.1007/s12072-018-9913-7 · DOI · Paper page
  105. De Bruyn, 2013, Sandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity, Expert Opin Drug Metab Toxicol, 9, 589, 10.1517/17425255.2013.773973 · DOI
  106. Berger, 2015, Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell–cell interactions in vitro, Hepatology, 61, 1370, 10.1002/hep.27621 · DOI
  107. Takahashi, 2015, 3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells, Biosci Rep, 35, 10.1042/BSR20150034 · DOI · Paper page
  108. Sirenko, 2016, Phenotypic characterization of toxic compound effects on liver spheroids derived from iPSC using confocal imaging and three-dimensional image analysis, Assay Drug Dev Technol, 14, 381, 10.1089/adt.2016.729 · DOI
  109. Andria, 2010, Liver cell culture devices, Cell Med, 1, 55, 10.3727/215517910X519274 · DOI
  110. Kostadinova, 2013, A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity, Toxicol Appl Pharmacol, 268, 1, 10.1016/j.taap.2013.01.012 · DOI · Paper page
  111. Ohkura, 2014, Evaluation of human hepatocytes cultured by three-dimensional spheroid systems for drug metabolism, Drug Metab Pharmacokinet, 29, 373, 10.2133/dmpk.DMPK-13-RG-105 · DOI
  112. Takayama, 2013, 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing, Biomaterials, 34, 1781, 10.1016/j.biomaterials.2012.11.029 · DOI
  113. Nguyen, 2016, Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro, PLoS One, 11, e0158674, 10.1371/journal.pone.0158674 · DOI
  114. Ide, 2020, A novel evaluation method for determining drug-induced hepatotoxicity using 3D bio-printed human liver tissue, Toxicol Mech Methods, 30, 189, 10.1080/15376516.2019.1686795 · DOI
  115. Wang, 2018, Review fantastic medical implications of 3D-printing in liver surgeries, liver regeneration, liver transplantation and drug hepatotoxicity testing: a review, Int J Surg, 56, 1, 10.1016/j.ijsu.2018.06.004 · DOI
  116. Norona, 2016, Editor's highlight: modeling compound-induced fibrogenesis in vitro using three-dimensional bioprinted human liver tissues, Toxicol Sci, 154, 354, 10.1093/toxsci/kfw169 · DOI
  117. Schmidt, 2020, 3D-bioprinted HepaRG cultures as a model for testing long term aflatoxin B1 toxicity in vitro, Toxicol Rep, 7, 1578, 10.1016/j.toxrep.2020.11.003 · DOI
  118. Peck, 2020, Organs-on-chips in clinical pharmacology: putting the patient into the center of treatment selection and drug development, Clin Pharmacol Ther, 107, 181, 10.1002/cpt.1688 · DOI
  119. Viravaidya, 2004, Development of a microscale cell culture analog to probe naphthalene toxicity, Biotechnol Prog, 20, 316, 10.1021/bp0341996 · DOI
  120. Regev, 2014, Drug-induced liver injury and drug development: industry perspective, Semin Liver Dis, 34, 227, 10.1055/s-0034-1375962 · DOI
  121. Walker, 2020, The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development, Arch Toxicol, 94, 2559, 10.1007/s00204-020-02763-w · DOI
  122. Weaver, 2020, Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models, Nat Rev Drug Discov, 19, 131, 10.1038/s41573-019-0048-x · DOI
  123. Weaver, 2017, Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury, Expert Opin Drug Metab Toxicol, 13, 767, 10.1080/17425255.2017.1341489 · DOI
  124. McGill, 2018, The problem with predictive values: are we using the right metrics for preclinical prediction of drug hepatotoxicity?., Toxicol Sci, 165, 3, 10.1093/toxsci/kfy157 · DOI
  125. Ingelman-Sundberg, 2018, Current statistical metrics are pragmatic measures to compare the predictive quality of preclinical assays, Toxicol Sci, 165, 4, 10.1093/toxsci/kfy160 · DOI
  126. Atienzar, 2016, Key challenges and opportunities associated with the use of in vitro models to detect human DILI: integrated risk assessment and mitigation plans, BioMed Res Int, 2016, 10.1155/2016/9737920 · DOI
  127. Xu, 2008, Cellular imaging predictions of clinical drug-induced liver injury, Toxicol Sci, 105, 97, 10.1093/toxsci/kfn109 · DOI
  128. Thompson, 2016, Reactive metabolites: current and emerging risk and hazard assessments, Chem Res Toxicol, 29, 505, 10.1021/acs.chemrestox.5b00410 · DOI
  129. Iorga, 2017, Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis, Int J Mol Sci, 18, 1018, 10.3390/ijms18051018 · DOI
  130. Nakayama, 2009, A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding, Drug Metab Dispos, 37, 1970, 10.1124/dmd.109.027797 · DOI
  131. Norman, 2020, Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies, J Med Chem, 63, 11397, 10.1021/acs.jmedchem.0c00524 · DOI
  132. Ramachandran, 2018, Oxidative stress and acute hepatic injury, Curr Opin Toxicol, 7, 17, 10.1016/j.cotox.2017.10.011 · DOI
  133. Chen, 2017, Activation of the Nrf2 signaling pathway in usnic acid-induced toxicity in HepG2 cells, Arch Toxicol, 91, 1293, 10.1007/s00204-016-1775-y · DOI
  134. Anthérieu, 2013, Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells, Hepatology, 57, 1518, 10.1002/hep.26160 · DOI
  135. Han, 2013, Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria, Trends Pharmacol Sci, 34, 243, 10.1016/j.tips.2013.01.009 · DOI
  136. Boelsterli, 2007, Mitochondrial abnormalities—a link to idiosyncratic drug hepatotoxicity?., Toxicol Appl Pharmacol, 220, 92, 10.1016/j.taap.2006.12.013 · DOI
  137. Begriche, 2011, Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver, J Hepatol, 54, 773, 10.1016/j.jhep.2010.11.006 · DOI
  138. Pessayre, 2010, Mitochondrial involvement in drug-induced liver injury, Handb Exp Pharmacol, 311, 10.1007/978-3-642-00663-0_11 · DOI
  139. Porceddu, 2012, Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria, Toxicol Sci, 129, 332, 10.1093/toxsci/KFS197 · DOI
  140. Marroquin, 2007, Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants, Toxicol Sci, 97, 539, 10.1093/toxsci/kfm052 · DOI
  141. Rana, 2019, Evaluation of in vitro mitochondrial toxicity assays and physicochemical properties for prediction of organ toxicity using 228 pharmaceutical drugs, Chem Res Toxicol, 32, 156, 10.1021/acs.chemrestox.8b00246 · DOI
  142. Nadanaciva, 2012, Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform, J Bioenerg Biomembr, 44, 421, 10.1007/s10863-012-9446-z · DOI
  143. Eakins, 2016, A combined in vitro approach to improve the prediction of mitochondrial toxicants, Toxicol Vitro, 34, 161, 10.1016/j.tiv.2016.03.016 · DOI
  144. Tirmenstein, 2002, Effects of troglitazone on HepG2 viability and mitochondrial function, Toxicol Sci, 69, 131, 10.1093/toxsci/69.1.131 · DOI
  145. Dykens, 2008, In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone, Toxicol Sci, 103, 335, 10.1093/toxsci/kfn056 · DOI
  146. Hynes, 2013, A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays, Toxicol Vitro, 27, 560, 10.1016/j.tiv.2012.11.002 · DOI
  147. Moran, 2014, Bulk autophagy, but not mitophagy, is increased in cellular model of mitochondrial disease, Biochim Biophys Acta, 1842, 1059, 10.1016/j.bbadis.2014.03.013 · DOI
  148. Cotan, 2011, Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts, FASEB J, 25, 2669, 10.1096/fj.10-165340 · DOI
  149. Moles, 2018, Mitochondrial–lysosomal axis in acetaminophen hepatotoxicity, Front Pharmacol, 9, 453, 10.3389/fphar.2018.00453 · DOI
  150. Jung, 2020, Diclofenac impairs autophagic flux via oxidative stress and lysosomal dysfunction: implications for hepatotoxicity, Redox Biol, 37, 101751, 10.1016/j.redox.2020.101751 · DOI
  151. Torres, 2019, Endoplasmic reticulum stress-induced upregulation of STARD1 promotes acetaminophen-induced acute liver failure, Gastroenterology, 157, 552, 10.1053/j.gastro.2019.04.023 · DOI
  152. Sano, 2013, ER stress-induced cell death mechanisms, Biochim Biophys Acta, 1833, 3460, 10.1016/j.bbamcr.2013.06.028 · DOI · Paper page
  153. Liu, 2012, Endoplasmic reticulum stress modulates liver inflammatory immune response in the pathogenesis of liver ischemia and reperfusion injury, Transplantation, 94, 211, 10.1097/TP.0b013e318259d38e · DOI
  154. Ren, 2016, Endoplasmic reticulum stress induction and ERK1/2 activation contribute to nefazodone-induced toxicity in hepatic cells, Toxicol Sci, 154, 368, 10.1093/toxsci/kfw173 · DOI
  155. Chen, 2015, Endoplasmic reticulum stress and store-operated calcium entry contribute to usnic acid-induced toxicity in hepatic cells, Toxicol Sci, 146, 116, 10.1093/toxsci/kfv075 · DOI
  156. Mosedale, 2017, Drug-induced liver injury: advances in mechanistic understanding that will inform risk management, Clin Pharmacol Ther, 101, 469, 10.1002/cpt.564 · DOI
  157. Yang, 2013, An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters, J Pharm Sci, 102, 3037, 10.1002/jps.23584 · DOI
  158. Garzel, 2014, The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity, Drug Metab Dispos, 42, 318, 10.1124/dmd.113.054189 · DOI
  159. Ulzurrun, 2013, Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury, Liver Int, 33, 1378, 10.1111/liv.12193 · DOI
  160. Stieger, 2017, Model systems for studying the role of canalicular efflux transporters in drug-induced cholestatic liver disease, J Pharm Sci, 106, 2295, 10.1016/j.xphs.2017.03.023 · DOI
  161. Kock, 2014, Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4, Drug Metab Dispos, 42, 665, 10.1124/dmd.113.054304 · DOI
  162. Morgan, 2010, Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development, Toxicol Sci, 118, 485, 10.1093/toxsci/kfq269 · DOI · Paper page
  163. Jemnitz, 2010, Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human, Toxicol Sci, 115, 80, 10.1093/toxsci/kfq044 · DOI
  164. Ellis, 2010, The use of human hepatocytes to investigate bile acid synthesis, Methods Mol Biol, 640, 417, 10.1007/978-1-60761-688-7_22 · DOI
  165. Yang, 2016, Sandwich-cultured hepatocytes as a tool to study drug disposition and drug-induced liver injury, J Pharm Sci, 105, 443, 10.1016/j.xphs.2015.11.008 · DOI
  166. Guo, 2006, Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells, Mol Divers, 10, 349, 10.1007/s11030-006-9038-0 · DOI
  167. Pedersen, 2013, Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11), Toxicol Sci, 136, 328, 10.1093/toxsci/kft197 · DOI
  168. Oorts, 2016, Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes, Toxicol Vitro, 34, 179, 10.1016/j.tiv.2016.03.008 · DOI
  169. Lu, 2015, FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach, Sci Rep, 5, 8114, 10.1038/srep08114 · DOI
  170. Burbank, 2016, Early alterations of bile canaliculi dynamics and the Rho kinase/myosin light chain kinase pathway are characteristics of drug-induced intrahepatic cholestasis, Drug Metab Dispos, 44, 1780, 10.1124/dmd.116.071373 · DOI
  171. Racanelli, 2006, The liver as an immunological organ, Hepatology, 43, S54, 10.1002/hep.21060 · DOI · Paper page
  172. Robinson, 2016, Liver immunology and its role in inflammation and homeostasis, Cell Mol Immunol, 13, 267, 10.1038/cmi.2016.3 · DOI · Paper page
  173. Papay, 2009, Drug-induced liver injury following positive drug rechallenge, Regul Toxicol Pharmacol, 54, 84, 10.1016/j.yrtph.2009.03.003 · DOI
  174. Ju, 2012, Role of immune reactions in drug-induced liver injury (DILI), Drug Metab Rev, 44, 107, 10.3109/03602532.2011.645579 · DOI
  175. Clare, 2017, Genetic factors influencing drug-induced liver injury: do they have a role in prevention and diagnosis?., Curr Hepatol Rep, 16, 258, 10.1007/s11901-017-0363-9 · DOI
  176. Daly, 2009, HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI
  177. Monshi, 2013, Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI
  178. Nicoletti, 2019, Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles, Clin Pharmacol Ther, 106, 245, 10.1002/cpt.1375 · DOI
  179. Hautekeete, 1999, HLA association of amoxicillin-clavulanate-induced hepatitis, Gastroenterology, 117, 1181, 10.1016/S0016-5085(99)70404-X · DOI
  180. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI
  181. Stephens, 2013, HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity, PLoS One, 8, e68111, 10.1371/journal.pone.0068111 · DOI
  182. O'Donohue, 2000, Co-amoxiclav jaundice: clinical and histological features and HLA class II association, Gut, 47, 717, 10.1136/gut.47.5.717 · DOI
  183. Donaldson, 2010, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury, J Hepatol, 53, 1049, 10.1016/j.jhep.2010.05.033 · DOI
  184. Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458 · DOI
  185. Parham, 2016, Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1∗07:01, Pharmacogenomics J, 16, 180, 10.1038/tpj.2015.40 · DOI
  186. Pollmacher, 1996, Effects of clozapine on plasma cytokine and soluble cytokine receptor levels, J Clin Psychopharmacol, 16, 403, 10.1097/00004714-199610000-00011 · DOI
  187. Kato, 2017, Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes, Chem Res Toxicol, 30, 1327, 10.1021/acs.chemrestox.7b00065 · DOI
  188. Jee, 2021, Idiosyncratic drug-induced liver injury: mechanistic and clinical challenges, Int J Mol Sci, 22, 2954, 10.3390/ijms22062954 · DOI
  189. Kouwenhoven, 2001, Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes, Clin Diagn Lab Immunol, 8, 1248, 10.1128/CDLI.8.6.1248-1257.2001 · DOI
  190. Pichler, 2004, The lymphocyte transformation test in the diagnosis of drug hypersensitivity, Allergy, 59, 809, 10.1111/j.1398-9995.2004.00547.x · DOI · Paper page
  191. Rive, 2013, Testing for drug hypersensitivity syndromes, Clin Biochem Rev, 34, 15
  192. Whritenour, 2017, Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response, J Immunotoxicol, 14, 31, 10.1080/1547691X.2016.1254305 · DOI · Paper page
  193. Usui, 2018, Application of in vitro T cell assay using human leukocyte antigen-typed healthy donors for the assessment of drug immunogenicity, Chem Res Toxicol, 31, 165, 10.1021/acs.chemrestox.8b00030 · DOI
  194. Oda, 2016, A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury, Toxicol Lett, 241, 60, 10.1016/j.toxlet.2015.10.029 · DOI
  195. Ogese, 2017, Characterization of drug-specific signaling between primary human hepatocytes and immune cells, Toxicol Sci, 158, 76, 10.1093/toxsci/kfx069 · DOI
  196. Cosgrove, 2009, Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity, Toxicol Appl Pharmacol, 237, 317, 10.1016/j.taap.2009.04.002 · DOI
  197. Zou, 2010, Oxidative stress is important in the pathogenesis of liver injury induced by sulindac and lipopolysaccharide cotreatment, Toxicology, 272, 32, 10.1016/j.tox.2010.03.015 · DOI
  198. Fredriksson, 2011, Diclofenac inhibits tumor necrosis factor-alpha-induced nuclear factor-kappaB activation causing synergistic hepatocyte apoptosis, Hepatology, 53, 2027, 10.1002/hep.24314 · DOI
  199. Beggs, 2015, Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related, Toxicology, 331, 35, 10.1016/j.tox.2015.03.002 · DOI
  200. Oda, 2021, An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury, Arch Toxicol, 95, 149, 10.1007/s00204-020-02882-4 · DOI

200 of 386 shown

Cited by

Sorted by citations

Metadata

Authors
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2021-12
Volume
11
Issue
12
Pages
3685-3726
ISSN
2211-3835
DOI
10.1016/j.apsb.2021.11.013
PMC
PMC8727925
Cited by
70
References
33
Language
en
Licence
Funders
  • European Cooperation in Science and Technology
  • Instituto de Salud Carlos III
  • European Regional Development Fund (PI18/01804, PI19-00883, PT20/00127, PY18-3364, UMA18-FEDERJA-194)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review